ERBB2 AMPLIFICATION LEVEL AND PTPN2 GAIN AS POTENTIAL PROGNOSTIC FACTORS IN METASTATIC HER2-POSITIVE BREAST CANCER TREATED WITH TRASTUZUMAB

被引：0
|
作者：
Ellegard, Sander [1 ]
Veenstra, Cynthia [1 ]
Perez-Tenorio, Giseh [1 ]
Hallbeck, Anna-Lotta [1 ]
Elander, Nils [1 ]
Stal, Olle [1 ]
机构：
[1] Univ Hosp Linkoping, Oncol, Linkoping, Sweden
来源：
BREAST | 2017年 / 36卷
关键词：
D O I：
10.1016/S0960-9776(17)30690-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO71
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [21] TRASTUZUMAB EMTANSINE FOR THE TREATMENT OF HER2-POSITIVE METASTATIC BREAST CANCER
    Haddley, K.
    DRUGS OF TODAY, 2013, 49 (11) : 701 - 715
  • [22] Trastuzumab Deruxtecan in cerebral metastatic HER2-positive Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2025, 85 (04) : 354 - 354
  • [23] Trastuzumab beyond progression in HER2-positive metastatic breast cancer
    Al-Naqqash, Manwar
    Jasim Al-Serarati, Waleed
    Farooq Kareem, Tara
    BREAST JOURNAL, 2021, 27 (03): : 297 - 299
  • [24] Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab
    Kurebayashi, Junichi
    Kanomata, Naoki
    Yamashita, Tetsumasa
    Shimo, Toshiro
    Mizutoh, Akiko
    Moriya, Takuya
    Sonoo, Hiroshi
    BREAST CANCER, 2015, 22 (03) : 292 - 299
  • [25] Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab
    Junichi Kurebayashi
    Naoki Kanomata
    Tetsumasa Yamashita
    Toshiro Shimo
    Akiko Mizutoh
    Takuya Moriya
    Hiroshi Sonoo
    Breast Cancer, 2015, 22 : 292 - 299
  • [26] Components of the PI3K/Akt pathway as prognostic factors in metastatic HER2-positive breast cancer treated with trastuzumab
    Veenstra, C.
    Ellegard, S.
    Perez-Tenorio, G.
    Fagerstrom, V.
    Garsjo, J.
    Briedis, K.
    Sundqvist, M.
    Malmstrom, A.
    Wingren, S.
    Stal, O.
    ANNALS OF ONCOLOGY, 2016, 27
  • [27] Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
    Modi, Shanu
    Saura, Cristina
    Yamashita, Toshinari
    Park, Yeon Hee
    Kim, Sung-Bae
    Tamura, Kenji
    Andre, Fabrice
    Iwata, Hiroji
    Ito, Yoshinori
    Tsurutani, Junji
    Sohn, Joohyuk
    Denduluri, Neelima
    Perrin, Christophe
    Aogi, Kenjiro
    Tokunaga, Eriko
    Im, Seock-Ah
    Lee, Keun Seok
    Hurvitz, Sara A.
    Cortes, Javier
    Lee, Caleb
    Chen, Shuquan
    Zhang, Lin
    Shahidi, Javad
    Yver, Antoine
    Krop, Ian
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (07): : 610 - 621
  • [28] Trastuzumab In HER2-Positive Metastatic Gastric Cancer
    Croxtall, Jamie D.
    McKeage, Kate
    DRUGS, 2010, 70 (17) : 2259 - 2267
  • [29] LEVEL OF HER2/NEU GENE (HER2) AMPLIFICATION IN PRIMARY AND METASTATIC SITES IN HER2-POSITIVE METASTATIC BREAST CANCER AND RESPONSE TO TRASTUZUMAB(T)-BASED THERAPY
    Gullo, G.
    Bettio, D.
    Zuradelli, M.
    Giordano, L.
    Masci, G.
    Bareggi, C.
    Salvini, P.
    Venci, A.
    Santoro, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 101 - 101
  • [30] Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
    Ronnlund, Caroline
    Sifakis, Emmanouil G.
    Schagerholm, Caroline
    Yang, Qiao
    Karlsson, Emelie
    Chen, Xinsong
    Foukakis, Theodoros
    Weidler, Jodi
    Bates, Michael
    Fredriksson, Irma
    Robertson, Stephanie
    Hartman, Johan
    BREAST CANCER RESEARCH, 2024, 26 (01)
12345